ANNUAL REPORT - Department of Biotechnology
ANNUAL REPORT - Department of Biotechnology
ANNUAL REPORT - Department of Biotechnology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
the pathogenesis <strong>of</strong> JE. It has been seen that JEV<br />
infection activates microglia both morphologically<br />
and functionally; infection leads to an elevation <strong>of</strong><br />
proinflammatory mediators for which microglia are<br />
predominantly responsible and the cytotoxins<br />
released from activated microglia are instrumental in<br />
inducing neuronal death that accompanies JE.<br />
Avian Influenza (H5N1) Virus<br />
A brain-storming session was organized by the<br />
<strong>Department</strong> on the status <strong>of</strong> Avian Influenza Research<br />
in India: Past, Present and Future on September 9,<br />
2006. Experts from India and USA participated and<br />
deliberated. The priority areas identified are genetic<br />
diversity, pathogenesis and zoonosis, diagnostics,<br />
vaccines. Accordingly, the <strong>Department</strong> has funded two<br />
R&D projects on development <strong>of</strong> a cost effective and<br />
easily up-scaleable multivalent vaccine using a novel<br />
yeast expressed virus like particles approach against<br />
the deadly Influenza A (H5N1) virus and molecular<br />
biology studies on the pathogenic strain <strong>of</strong> H5N1 virus<br />
(Indian isolate): protein-protein interaction based<br />
approach to study molecular evolution <strong>of</strong> the virus from<br />
its non-pathogenic strain at ICGEB, New Delhi.<br />
Malaria<br />
The project implemented at ICGEB, NIMR, New<br />
Delhi and Ispat General Hospital, Rourkela the cell<br />
bank and technology for production <strong>of</strong> recombinant<br />
PfMSP-119 and PfF2 were transferred to Bharat<br />
Biotech International Limited (BBIL), Hyderabad for<br />
developing master cell bank and master working cell<br />
bank for characterization. The BBIL has successfully<br />
produced cGMP grade material <strong>of</strong> three consistent<br />
batches at 10L scale for human clinical trial and<br />
toxicological studies. Efforts have been made to<br />
scale up to 50-100L ferment.<br />
Malaria vaccine trial site has been developed at<br />
Sundergarh District <strong>of</strong> Orissa to evaluate the malaria<br />
candidate vaccinogens PfMSP-119 and PfF2 through<br />
collection <strong>of</strong> clinical, entomological and molecular<br />
epidemiological /immunological indicators from the<br />
study. The group conducted longitudinal<br />
DBT Annual Report 2006-07<br />
106<br />
entomological surveys in two indicator villages each<br />
from forest and plan area. A total <strong>of</strong> 11 anopheline<br />
species from forest area and 10 speciies from plain<br />
area were recorded. It was observed that Anopheles<br />
Culificacies was the most predominants species and<br />
accounted for 41.2 and 36.5% <strong>of</strong> the total<br />
anophelines in forest and plain area respectively.<br />
Further observed that An. Fluviatilis was restricted to<br />
only forest area and its prevalence rate was 1.1%. It<br />
was measured that the antibody levels against<br />
PfMSP1 19,<br />
EBA 175 and TRAP antigens in 222 (110<br />
from forest and 112 from plain areas) and 248 (138<br />
from forest and 110 from plain areas) blood samples<br />
collected during low and high transmission seasons,<br />
respectively. The results suggest that there was a<br />
boosting in antibody production against these<br />
molecules by natural infectious in these individuals.<br />
The level <strong>of</strong> antibodies in study groups appeared to<br />
be related to their exposures to the parasite during<br />
high transmission phase. Update on progress on the<br />
project was reviewed in the month <strong>of</strong> January, 2007<br />
and decided to validate the data generated to initiate<br />
phase I/II clinical trial with malaria vaccinogens<br />
through national and international experts.<br />
A new multi-centric project entitled “Use <strong>of</strong><br />
artemisinin and curcumin combination in treatment <strong>of</strong><br />
uncomplicated P.falciparum malaria” was<br />
implemented at five institutions i.e. at National<br />
Institute <strong>of</strong> Malaria Research, Delhi; Indian Institute<br />
<strong>of</strong> Science, Bangalore; NIMR Field station,<br />
Rourkela; Ispat General Hospital, Rourkela and<br />
NIMR, Jabalpur.<br />
Another project implemented at IISc., Bangalore on<br />
development <strong>of</strong> candidate anti-malarials based on<br />
new drug targets, analyzed Pfcrt mutation as a<br />
marker for chloroquine resistance in 200 P.<br />
falciparum infected patients. Analysis <strong>of</strong> Pfmdr1 gene<br />
as a marker for chloroquine resistance has revealed<br />
that only around 30% <strong>of</strong> the Indian samples show the<br />
N86Y mutation, although in Africa there is a good<br />
correlation between K76T-Pfcrt mutation and N86Ymdr1<br />
mutation. The high prevalence <strong>of</strong> K76T- Pfcrt<br />
mutation in the Indian isolates <strong>of</strong> P.falciarum is a